Literature DB >> 2765512

Refolding of denatured ribonuclease observed by size exclusion chromatography.

W Shalongo1, M V Jagannadham, C Flynn, E Stellwagen.   

Abstract

The unfolding and refolding of pancreatic ribonuclease have been observed by absorbance, fluorescence, and size exclusion chromatographic measurements in solutions of guanidinium chloride continuously maintained at pH 6.0 and 4 degrees C. The spectral measurements were fitted with a minimal number of kinetic phases while the chromatographic measurements were simulated from an explicit mechanism. All of the measurements are consistent with a minimal mechanism involving seven components. The folded components include the native protein and two transiently stable intermediates each having the same hydrodynamic volume. The intermediate having all native peptide isomers has an unfolding midpoint in 3.8 M denaturant while the intermediate having one nonnative peptide isomer has an unfolding midpoint in 1.3 M denaturant. The unfolded protein is distributed among four components having the same hydrodynamic volume but differing peptide isomers. At equilibrium, 10% of the denatured protein has all native isomers, 60% has one nonnative isomer, 5% has a different nonnative isomer, and 25% has both nonnative isomers. In low denaturant concentrations, the dominant component with one nonnative isomer can refold to transiently populate the compact intermediate with the same nonnative isomer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765512     DOI: 10.1021/bi00437a045

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  RhNGF slow unfolding is not due to proline isomerization: possibility of a cystine knot loop-threading mechanism.

Authors:  L R De Young; L E Burton; J Liu; M F Powell; C H Schmelzer; N J Skelton
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

2.  Chromatographic methods for quantitative analysis of native, denatured, and aggregated basic fibroblast growth factor in solution formulations.

Authors:  V Sluzky; Z Shahrokh; P Stratton; G Eberlein; Y J Wang
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.